NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. The firm is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and proprietary sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a proprietary platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.
Follow-Up Questions
NRXBF 주식의 가격 성능은 어떻습니까?
NRXBF의 현재 가격은 $0.7421이며, 전 거래일에 decreased 0% 하였습니다.
Nurexone Biologic Inc의 주요 사업 주제나 업종은 무엇입니까?
Nurexone Biologic Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Nurexone Biologic Inc의 시가총액은 얼마입니까?
Nurexone Biologic Inc의 현재 시가총액은 $60.4M입니다
Nurexone Biologic Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 5명의 분석가가 Nurexone Biologic Inc에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 5명의 매수, 1명의 보유, 0명의 매도, 그리고 3명의 강력한 매도를 포함합니다
